

# 해외 바이오의약품 임상 현황 ('23년 7월 1주)

한국바이오의약품협회, 2023.07.11.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2023.07.03.~2023.07.09.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

## ○ 미국 9건

| NCT Number                  | Title   | Interventions   | Sponsor/Collaborators   | Phases          | URL   |
|-----------------------------|---|---|---|-----------------|---|
| <a href="#">NCT05928585</a> | A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers   | Drug: HIB210 Drug: Placebo  | HI-Bio  | Phase 1         | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05928585&amp;rank=1</a> |
| <a href="#">NCT05539365</a> | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer   | Biological: Alpha-type-1 Polarized Dendritic Cells Procedure: Biopsy Procedure: Computed Tomography Procedure: Leukapheresis Biological: Pembrolizumab Other: Quality-of-Life Assessment      | Roswell Park Cancer Institute   | Phase 2         | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05539365&amp;rank=1</a> |
| <a href="#">NCT05443971</a> | Durvalumab and Grid Therapy for the Treatment of Non-small Cell Lung Cancer in Patients Who Progressed During or After Treatment With the PACIFIC Regimen   | Biological: Durvalumab Radiation: Radiation Therapy   | Mayo Clinic   | Phase 2         | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05443971&amp;rank=1</a> |
| <a href="#">NCT04715191</a> | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors  | Genetic: CARE T cells Drug: Cytoxin Drug: Fludara   | Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine   | Phase 1         | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT04715191&amp;rank=1</a> |
| <a href="#">NCT05886491</a> | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia  | Drug: GDX012 Drug: Chemotherapy Agents  | Takeda  | Phase 1 Phase 2 | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05886491&amp;rank=1</a> |
| <a href="#">NCT05756569</a> | Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology   | Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Enfortumab Vedotin Procedure: Magnetic Resonance Imaging Biological: Pembrolizumab Other: Questionnaire Administration | Emory University National Cancer Institute (NCI) Seagen Inc. Astellas Pharma Inc Merck Sharp & Dohme LLC                            | Phase 2         | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05756569&amp;rank=1</a> |
| <a href="#">NCT05852691</a> | A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | Drug: RO7247669 Drug: Pembrolizumab Drug: Nab-Paclitaxel  | Hoffmann-La Roche   | Phase 2         | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05852691&amp;rank=1</a> |
| <a href="#">NCT05671757</a> | Daratumumab in Primary Antiphospholipid Syndrome  | Biological: Daratumumab   | National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) PPD Rho Federal Systems Division, Inc. | Phase 1 Phase 2 | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05671757&amp;rank=1</a> |
| <a href="#">NCT05726227</a> | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight   | Drug: Semaglutide Drug: Placebo   | Novo Nordisk A/S  | Phase 3         | <a href="#">https://clinicaltrials.gov/ct2/show/study?term=NCT05726227&amp;rank=1</a> |

# 해외 바이오의약품 임상 현황 ('23년 7월 1주)

한국바이오의약품협회, 2023.07.11.

## ○ 영국 1건

| NCT Number                  | Title   | Interventions                   | Sponsor/Collaborators | Phases  | URL   |
|-----------------------------|---|---------------------------------|-----------------------|---------|---|
| <a href="#">NCT05726227</a> | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Drug: Semaglutide Drug: Placebo | Novo Nordisk A/S      | Phase 3 | <a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05726227</a> |

## ○ 독일 1건

| NCT Number                  | Title   | Interventions                   | Sponsor/Collaborators | Phases  | URL   |
|-----------------------------|---|---------------------------------|-----------------------|---------|---|
| <a href="#">NCT05726227</a> | A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Drug: Semaglutide Drug: Placebo | Novo Nordisk A/S      | Phase 3 | <a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05726227</a> |

## ○ 중국 3건

| NCT Number                  | Title   | Interventions  | Sponsor/Collaborators  | Phases  | URL   |
|-----------------------------|---|--|--|---------|---|
| <a href="#">NCT05914376</a> | Safety of Recombinant Human IL-21 Oncolytic Vaccinia Virus Injection ( hV01) in Advanced Tumors | Biological: Recombinant human IL-21 oncolytic vaccinia virus injection | Hangzhou Converd Co., Ltd.   | Phase 1 | <a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05914376</a> |
| <a href="#">NCT05867563</a> | Clinical Trial Evaluating the Safety of the TQB2103 for Injection                               | Drug: TQB2103 for injection  | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | <a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05867563</a> |
| <a href="#">NCT05886244</a> | Ecuzumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China          | Drug: Ecuzumab   | Alexion AstraZeneca  | Phase 3 | <a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05886244</a> |